Abstract
Background Lung cancer remains the leading cause of cancer-related mortality, with brain metastases (BMs) significantly worsening prognosis and quality of life. The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for non-small cell lung cancer (NSCLC). However, precise prognostic tools are essential to optimize clinical decision-making in this context.
Methods The Brain-Lung Immunotherapy Prognostic (BLIP) score was developed based on a retrospective cohort of NSCLC patients treated with ICIs at Karolinska University Hospital, Sweden. Prognostic factors were identified using both univariate and multivariate Cox regression analyses. Internal validation was conducted using bootstrap resampling, penalized Cox regression, k-fold cross-validation, and receiver operating characteristics (ROC) analysis. External validation was performed using an independent cohort from Sotiria Thoracic Diseases Hospital of Athens, Greece.
Results From a total cohort of 1844 patients screened across both study sites, 152 patients from Karolinska University Hospital and 116 from Sotiria Thoracic Diseases Hospital of Athens, Greece, were included in the final analysis. Key prognostic factors influencing outcomes included histology, actionable mutations, age at BM diagnosis, and the number of BMs. The BLIP score effectively stratified patients into two prognostic groups: “Good” and “Poor”, with a median overall survival (OS) of 15 and 7 months, respectively (hazard ratio [HR]: 0.4; p < 0.0001). External validation confirmed these findings, showing a significantly lower risk of death for the “Good” group compared to the “Poor” group (HR: 0.49; p = 0.0063). The model’s robust prognostic performance was confirmed with an area under the ROC curve of 0.87, highlighting its accuracy in predicting survival outcomes.
Conclusion The BLIP score provides a reliable, validated prognostic tool for NSCLC patients with BMs undergoing ICI therapy. By integrating both molecular and clinical variables, it offers significant improvements over existing models. Prospective validation could further support its use in personalized treatment strategies, improving clinical outcomes and patient management.
Highlights
The BLIP score is a new prognostic tool for NSCLC.
It focuses on patients with brain metastases undergoing immunotherapy.
The score integrates clinical and molecular factors.
Internal validation showed strong prognostic power and reliability.
External validation confirmed effectiveness across diverse patient populations.
Key factors include histology, actionable mutations, age, and brain metastases count.
The score stratifies patients into “Good” and “Poor” groups.
The BLIP score aids in personalized treatment decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.S. received funding from the Stockholm Cancer Society (grant number: 009618). G.T. was supported by Region Stockholm (clinical postdoctoral appointment). S.E. received funding from the Swedish Cancer Society (CAN2023/29191057), the Stockholm County Council (987911), King Gustaf V Jubilee Fund (204053), and the Sjoberg Foundation (2022-2024). A.K. was supported and funded by research grants from the European Society for Medical Oncology (ESMO) and the Hellenic Society for Medical Oncology (HeSMO). The funders had no role in the collection, the interpretation of data, or the writing of the manuscript. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the regional ethical review board at Region Stockholm (approval number: 2020-02636). The ethical board waived the need for informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
